About Spinogenix
Spinogenix is a private company based in Los Angeles, California. It has reported $24,652,720 raised in seven offerings on Form D since October 2017. Its chief executive is Stella Sarraf, Ph.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | Mar 9, 2026 | $10,606,566of $35.0M target | 5 | $2.1M | EquityRule 506(b) | Form D ↗ |
| Jun 10, 2024 | Jun 21, 2024 | $2,800,000of $25.0M target | 3 | $933K | EquityRule 506(b) | Form D ↗ |
| Jul 27, 2023 | Aug 10, 2023 | $5,199,985fully sold | 3 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Sep 1, 2022 | Sep 12, 2022amended Sep 13, 2022 | $3,335,431fully sold | 3 | $1.1M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 19, 2021 | Feb 24, 2021 | $1,557,403of $2.2M target | 22 | $70,791 | EquityRule 506(b) | Form D ↗ |
| Aug 29, 2019 | Sep 17, 2020 | $250,000fully sold | 12 | $20,833 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Sep 20, 2017 | Oct 4, 2017amended May 7, 2018 | $903,335fully sold | 10 | $90,334 | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, seven offerings | $24,652,720 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Spinogenix's Form D filed Mar 9, 2026.
Earlier filings also listed Stella Sarraf (executive officer and director, last listed Jun 2024), Peter Vanderklish (executive officer, last listed Jun 2024), Mervyn Turner (director, last listed Jun 2024), Dan Albosta (executive officer, last listed Jun 2024), Vincent Simmon (executive officer and director, last listed Aug 2023), Franz Hefti (director, last listed Feb 2021) and Josh Swartz (director, last listed May 2018).